Deals & Cases

E3 Holding AG acquires the clean-tek group

E3 Holding AG, Germany, has acquired the clean-tek group from Felix Ritter.

Clean-tek is one of the pioneers in cleanroom technology - technology for sensitive areas such as pharmaceutical production, medical technology,...

AMR Action Fund invests in BioVersys AG

The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland.

Invision launches CHF 145m continuation fund

Invision has launched and successfully closed Invision Logistics LP, a CHF 145m continuation fund for the further development of Schneider Group.

Resistell AG closes series B first tranche of CHF 8.5m

Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5m from new and existing investors.

AFINUM has sold its stake in Cotta Collection AG Upholstered Furniture-Group to L-GAM and to Gschwend AG

AFINUM has sold its stake in Cotta Collection AG Upholstered Furniture-Group to L-GAM and to Gschwend AG.

Cotta is a manufacturer of upholstered furniture in the low to medium price segment with two plants in Poland and one plant in Romania.

Hangzhou GreatStar Industrial lists GDRs on SIX Swiss Exchange

On 15 November 2022, Hangzhou GreatStar Industrial Co., Ltd., whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX Swiss Exchange.

Anokion raises USD 35m Financing

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.

Oculis SA and European Biotech Acquisition Corp announce business combination

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive business combination agreement.

Norgine Ventures provides Debt Financing to Lunaphore

Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies.

Versantis to be sold to GENFIT

Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases is to be sold to Genfit SA (NASDAQ: GNFT).